Geoff von Maltzahn (L) and David Davidson
David Davidson’s R&D odyssey takes him out of bluebird to another biotech startup with big plans to transform therapy
David Davidson’s nearly decade-long stretch as the chief medical officer at bluebird bio ran the full gamut of drug hunting events: Remarkable scientific pioneering and clinical development at a one-time darling of the industry, with a rocky but ultimately successful regulatory run getting breakthrough cell and gene therapy drugs up to and across the finish line, all while getting a hard look at the tough competitive landscape that has taken shape in biotech’s boom years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
